Latest Articlesddd
Juno Therapeutics (JUNO) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical …
Good news is not always great news that makes a difference. In the drug industry, clinical …
PsiOxus Therapeutics’ adenovirus product in combination with Opdivo (nivo-lumab) for late-stage cancers. Bristol-Myers Squibb (BMY) …
- Tesaro's (TSRO) drug niraparib significantly improved progression-free survival for patients with ovarian cancer in both …
The Royal Divorce On Sunday, the next day after the announcement of the British referendum’s results, …
GRAFT VERSUS HOST DISEASE (GVHD) INCYTE (INCY) HAS SEVERAL GOOD NEWS. As a matter of fact, …
Le CompaGnon Part 2 Wednesday June 22, 2016 From the American Society of Clinical Oncology (ASCO) …
Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study …
Paratek Pharmaceuticals (PRTK) announced positive results from Phase 3 registration study comparing its once-daily, broad spectrum …
ARIAD Pharmaceuticals (ARIA) announced the initiation of a New Drug Application (NDA) submission for brigatinib, the …
CELATOR PHARMACEUTICALS Good News That Might Go to JAZZ Pharmaceuticals Celator Pharmaceuticals (CPXX): At the European …
SPARK Spark (NASDAQ: ONCE) is on its way to get an FDA approval of its first …
Le CompaGnon Part 1 TUESDAY June 14, 2016 The Eternal Market Games Unfortunately, the fabrication and …
Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration …
Prohost Letter #396 CELEBRATING MEMORIAL DAY - Wish you celebrated the Memorial Day. Memorial Day’s purpose was …
Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for …
Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 …
Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from …
Ionis Pharmaceuticals (IONS) stock plummeted when GlaxoSmithKline (GSK) stopped pursuing a late stage trial of Ionis-TTR …
GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
